Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition, Collaboration Agreements and Other (Details Narrative)

v3.22.2
Revenue Recognition, Collaboration Agreements and Other (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Apr. 08, 2022
Nov. 19, 2020
Dec. 12, 2019
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Research and development expense       $ 4,126,529   $ 2,480,764 $ 9,104,634 $ 5,722,196
Deferred revenue [1]       2,096,000 $ 33,000   2,096,000  
Revenue       1,062,500   1,062,500 $ 33,333
Bio NTech agreement [Member]                
Research and development expense $ 2,750,000              
Deferred revenue $ 2,750,000              
Revenue             1,100,000  
Revenue recognized       688,000     688,000  
License fee             375,000  
Accrued liabilities and other liabilities       2,100,000     2,100,000  
Award Agreement [Member] | Cystic Fibrosis Foundation [Member]                
Therapeutics development award   $ 4,200,000            
Proceeds from award   $ 484,000            
Additional milestone payment         321,000      
CFF Agreement [Member]                
Grants Receivable       3,600,000     3,600,000  
Additional milestone payment       4,500,000     4,500,000  
CFF Agreement [Member] | Accrued Expense and Other Current Liabilities [Member]                
Other Liabilities       $ 444,000 $ 899,000   $ 444,000  
Genentech Feasibility Study Agreement [Member] | Genentech [Member]                
Revenue     $ 33,000          
Agreement description     Under the terms of the Genentech Agreement, Genentech paid the Company a total of $100 thousand for the development of three molecules, or $33 thousand per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement          
[1] At June 30, 2022, the balance included $2,063 thousand related to the BioNTech Agreement and $33 thousand is related to the Genentech Agreement. At December 31, 2021, the balance of $33 thousand of deferred revenue was related to the Genentech Agreement. The balance of the BioNTech Agreement will be recognized evenly over the next nine months. (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).